Defining and managing imatinib resistance

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Imatinib is a highly effective therapy for chronic myeloid leukemia (CML).
• A subset of patients exhibit primary resistance or develop acquired resistance to imatinib.
• Resistance is often linked to specific mutations in the Abl kinase domain, hindering imatinib binding.

Purpose of the Study:

• To review the efficacy of imatinib and alternative Abl kinase inhibitors.
• To discuss mechanisms of resistance to imatinib therapy.
• To explore future therapeutic strategies for overcoming resistance and improving outcomes in CML.

Main Methods:

• Review of existing literature on imatinib, dasatinib, and nilotinib in CML treatment.
• Analysis of resistance mechanisms, including Abl kinase mutations.
• Discussion of clinical responses and limitations of current therapies.

Main Results:

• Imatinib offers good long-term remission prospects but is not universally effective.
• Dasatinib and nilotinib demonstrate efficacy in patients resistant to imatinib, particularly in chronic phase disease.
• Responses to alternative inhibitors are more limited in advanced disease and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), with frequent relapses.

Conclusions:

• While imatinib is a cornerstone therapy, resistance necessitates alternative treatment options.
• Second-generation inhibitors provide valuable alternatives for managing imatinib resistance.
• Ongoing research focuses on novel inhibitors to address challenging mutations like T315I and further reduce minimal residual disease.